What's Going On With Aralez Pharmaceuticals?

Shares of Aralez Pharmaceuticals Inc ARLZ, a specialty pharmaceutical company, fell nearly 11 percent on Wednesday ahead of an expected U.S. Food and Drug Administration ruling for its Yosparala therapy.

Aralez's therapy helps prevent cardiovascular disease in patients at-risk for aspirin induced ulcers. Some experts suggested it's "highly likely" Yosprala will be approved by the FDA by the September 14 PDUFA date, which would pave a path towards a commercial launch in the fourth quarter of 2016.

Shares of Aralez were trading lower by more than 12 percent in Thursday's pre-market trading session as no update was provided by the company. However, the stock was halted around 7:10 a.m. ET for pending news.